Johnson & Johnson

Eli Lilly

Bristol-Myers

Viatris

Pfizer

Merck

Zoetis

Royalty Pharma

Intra-Cellular Therapies

Jazz Pharmaceuticals

iShares U.S. Pharmaceuticals ETF

IHE tracks a broad-based, cap-weighted index of US pharmaceutical companies.

iShares U.S. Pharmaceuticals ETF is a pharmaceutical ETF offered by iShares, featuring an expense ratio of 0.39% and over $500 million in assets under management. In Q3, the healthcare sector reported earnings that exceeded expectations (+9.3%) and provided strong guidance for CV 2025, according to FactSet. The IHE prices are down 10% from their all-time high, with the next point of control 20% lower, while the maximum drawdown in the past 10 years was 40%.

IHE Contraction Is Not Justified By Fundamental Data

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on 05/01/2006.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

First Trust Nasdaq Pharmaceuticals ETF 

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Solid Q2 Earnings

Fidelity MSCI Consumer Staples ETF

Tema Obesity & Cardiometabolic ETF

iShares U.S. Aerospace & Defense ETF

iShares U.S. Healthcare ETF

iShares U.S. Consumer Goods ETF

Roundhill GLP-1 & Weight Loss ETF

Invesco Aerospace & Defense ETF

Global X Defense Tech ETF

Amplify Weight Loss Drug & Treatment ETF

Vanguard Consumer Staples ETF

Vanguard Utilities ETF

SPDR S&P Aerospace & Defense ETF

Consumer Staples Select Sector SPDR Fund

Utilities Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

IHE invests in large-cap U.S. pharmaceutical stocks with solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024, but its elevated valuation may not make it a good buy currently. Despite being a defensive play in an economic recession, IHE can still experience significant declines due to market sentiment.

IHE: Significant Growth Ahead, But Valuation Not Cheap (Rating Downgrade)

A Look at Pharma ETFs Post Q1 Earnings

iShares Core U.S. Aggregate Bond ETF

ARK 21Shares Bitcoin ETF

ARK Genomic Revolution Multi-Sector ETF

Aberdeen Standard Bloomberg All Commodity Strategy K-1 Free ETF

Abrdn Bloomberg Industrial Metals Strategy K-1 Free ETF

ProShares Bitcoin Strategy ETF

Fidelity Wise Origin Bitcoin Fund

VanEck Bitcoin Trust

iShares Bitcoin Trust

Global X Lithium & Battery Tech ETF

AdvisorShares Pure US Cannabis ETF

SPDR S&P 500 ETF Trust

SPDR S&P Biotech ETF

Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

Horizon Kinetics Medical ETF

Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.

ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook

Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.

JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus

Amgen

Ascendis Pharma

Cytokinetics

DexCom

Edwards Lifesciences

iShares Nasdaq Biotechnology ETF

Medtronic

Novo Nordisk

Viking Therapeutics

Vertex Pharmaceuticals

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

ROBO Global Healthcare Technology and Innovation ETF

iShares U.S. Medical Devices ETF

At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.

Time to Tap Healthcare ETFs on Nvidia's AI Ambition?

iShares Transportation Average ETF

Invesco S&P MidCap 400 Pure Growth ETF

Vanguard Financials ETF

Communication Services Select Sector SPDR Fund

Bargain hunting in a market where the S&P 500 is at record levels may seem like a daunting task, but it's not impossible.

Looking for Bargain Hunting? Top-Ranked ETFs to Buy

First Trust RBA American Industrial Renaissance ETF

Pacer US Cash Cows 100 ETF

Invesco S&P SmallCap Industrials ETF

Invesco S&P MidCap Momentum ETF

The S&P 500 hit an all-time high on Thursday despite despite a weaker-than-expected retail sales report.

5 ETFs at All-Time Highs as S&P 500 Rally Continues

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

Harbor Health Care ETF

Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.

ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat

Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF IHE on radar now. The fund recently hit a new 52-week high.

Pharma ETF (IHE) Hit a 52-Week High

Invesco Next Gen Connectivity ETF

Invesco PHLX Semiconductor ETF

Technology Select Sector SPDR Fund

The S&P 500 has been hovering around an all-time high. The chart indicates that, on average, investments made at record highs tend to perform better over the next five years, as quoted on Yahoo Finance.

Tech Leads S&P 500 to Highs: Does Further Rally Await ETFs?

iShares Russell 2000 ETF

Invesco KBW High Dividend Yield Financial ETF

NVIDIA

VanEck Vectors Semiconductor ETF

SPDR Portfolio S&P 500 High Dividend ETF

Vanguard Small Cap Value ETF

The January effect, while a famous market anomaly, is not as straightforward as it may seem. While Wall Street has been muted at the start of this year, it now seems that the anomaly has started to take place.

Has the January Effect Finally Taken Off? ETFs in Focus

iShares Core High Dividend ETF

iShares U.S. Oil & Gas Exploration & Production ETF

In the past three months, the S&P 500 has gained about 9.6%. We highlight a few ETFs that lost in the past three months but can rebound in 2024.

3 Beaten-Down ETFs to Buy for a Turnaround in 2024

WisdomTree U.S. High Dividend Fund

iShares U.S. Healthcare Providers ETF

iShares U.S. Energy ETF

SPDR S&P Dividend ETF

With Wall Street scaling new highs, there are some hidden gems, or Secret Santa as we call them, which could surprise investors with big returns this Christmas.

5 Secret Santa ETFs That Might Surprise You This Christmas

ARK Innovation ETF

Global X Health & Wellness Thematic ETF

A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking prowess.

New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade

Pharma ETFs in Focus Post Q3 Earnings

The iShares U.S. Pharmaceuticals ETF provides targeted exposure to the U.S. pharmaceutical industry but has a highly concentrated portfolio. The IHE ETF's top five holdings, including Eli Lilly and Johnson & Johnson, account for over 63% of the fund's total assets, posing a concentration risk. Compared to its peers, IHE has a lower expense ratio but higher concentration of holdings, which may increase risk for investors.

IHE: You Better Like Eli Lilly And Johnson & Johnson To Buy This

Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.

Eli Lilly Beats on Q3 Earnings: ETFs to Buy

Kenvue

Vanguard Health Care ETF

The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.

JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus

News for iShares U.S. Pharmaceuticals ETF ETF (IHE)